Trinity Biotech plc (TRIB)’s Financial Results Comparing With Palatin Technologies Inc. (NYSEAMERICAN:PTN)

Trinity Biotech plc (NASDAQ:TRIB) and Palatin Technologies Inc. (NYSEAMERICAN:PTN) compete with each other in the Diagnostic Substances sector. We will analyze and contrast their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trinity Biotech plc 97.06M 0.57 39.39M -1.84 0.00
Palatin Technologies Inc. 40.23M 3.79 8.42M 0.04 21.14

In table 1 we can see Trinity Biotech plc and Palatin Technologies Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Trinity Biotech plc -40.58% -61.7% -21.4%
Palatin Technologies Inc. 20.93% 46.8% 24.6%

Volatility and Risk

Trinity Biotech plc is 18.00% more volatile than Standard & Poor’s 500 due to its 1.18 beta. Competitively, Palatin Technologies Inc. is 76.00% more volatile than Standard & Poor’s 500, because of the 1.76 beta.

Liquidity

Trinity Biotech plc has a Current Ratio of 4.5 and a Quick Ratio of 2.9. Competitively, Palatin Technologies Inc.’s Current Ratio is 3.9 and has 3.9 Quick Ratio. Trinity Biotech plc’s better ability to pay short and long-term obligations than Palatin Technologies Inc.

Institutional and Insider Ownership

The shares of both Trinity Biotech plc and Palatin Technologies Inc. are owned by institutional investors at 56.2% and 21.7% respectively. About 11.2% of Trinity Biotech plc’s share are owned by insiders. Insiders Comparatively, owned 5.5% of Palatin Technologies Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Trinity Biotech plc -11.56% -17.46% -32.64% -46.39% -47.47% -49.02%
Palatin Technologies Inc. -8.57% -22.77% -32.73% -27.45% -13.49% -13.84%

For the past year Trinity Biotech plc’s stock price has bigger decline than Palatin Technologies Inc.

Summary

Palatin Technologies Inc. beats on 9 of the 11 factors Trinity Biotech plc.

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company’s principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include melanocortin peptide system program, including PL-8177 is a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, is a preclinical development candidate for treating ocular inflammation. In addition, the company develops natriuretic peptide system programs, including PL­3994, a natriuretic peptide receptor-A agonist for treatment of cardiovascular indications; and PL-5028, s dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.